Sotorasib plus Panitumumab in Refractory Colorectal Cancer with …
Oct 22, 2023 · KRAS G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only …
FDA approves sotorasib with panitumumab for colorectal cancer
On January 16, 2025, the Food and Drug Administration approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for adult patients with KRAS G12C-mutated …
FDA Approves First Colorectal Cancer Treatment that Targets G12C KRAS …
Jun 21, 2024 · The US Food and Drug Administration has granted accelerated approval for the targeted therapy adagrasib (Krazati ®) in combination with the drug cetuximab (Erbitux ®) for …
Adagrasib with or without Cetuximab in Colorectal Cancer with …
Dec 21, 2022 · Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has shown clinical activity in pretreated patients with several tumor types, including colorectal …
Treatment for KRAS G12C-mutated metastatic CRC approved by …
Jan 17, 2025 · "This new option validates our combination approach to improve outcomes for patients living with advanced KRAS G12C-mutated metastatic colorectal cancer." Colorectal …
KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer
Apr 15, 2024 · KRAS mutations contribute substantially to the overall colorectal cancer burden and have long been a focus of drug development efforts. After a lengthy preclinical road, …
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION …
Jan 17, 2025 · "This new combination approach is an important breakthrough for patients with KRAS G12C-mutated metastatic colorectal cancer, offering a new beneficial treatment option …
KRAS G12C inhibition in colorectal cancer - The Lancet
Dec 14, 2021 · Primary resistance to selective KRAS G12C inhibition is unusual, but treatment-induced resistance is rapidly developed, especially in metastatic colorectal cancer.
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer…
Dec 5, 2023 · Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C -positive CRC at 400 mg. Epidermal growth factor receptor has been recognized …
New Treatment for Metastatic Colorectal Cancer With Mutated KRAS G12C - LWW
Metastatic colorectal cancer patients with mutated KRAS G12C who received the KRAS inhibitor sotorasib in combination with panitumumab, a monoclonal antibody, had a longer progression …